Olga Goloubeva, Ph.D., M.Sc. Senior Biostatistician
Department:
Division of Biostatistics
University of Maryland Greenebaum Cancer Center
UMGCC Research Program:
Hormone Responsive Cancers Program
Education/Training:
College Degree:
B.Sc, M.Sc., Moscow Institute of Steel and Alloys, Moscow, Russia
M.Sc., Dalhousie University, Halifax, NS, Canada
Post Doctoral
Degree:
Ph.D., Moscow Institute of Highway Engineering, Moscow, Russia (accredited by the University of Toronto, Toronto, Canada)
Contact
Information:
Mailing Address:
UM Greenebaum Cancer Center
655 West Baltimore Street
Room 9-039
Baltimore, MD 21201
Email:
ogoloubeva@umm.edu
Phone:
410-328-8611
Research Interests:
Applied longitudinal analysis (linear and non-linear mixed-effects models); statistical methods in xenograft models (breast and prostate cancer) predictive of future clinical outcomes; statistical methods in molecular genetics; clinical trials design with group sequential and time-to-event method.
Publications:
LeBlanc R., Catley L., Hideshima T., Lentzsch S., Mitsiades C., Mitsiades N., Neuberg D., Goloubeva O., Pien C., Adams J., Gupta D., Richardson P., Munshi N., Anderson K., (2002), Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model, Cancer Research, 62(17): 4996-5000.
Kaste, S.C., Haight, A., Goloubeva, O.G., Xiong, X., Bowman, L.B., (2003), Nephrotoxicity of Iopamidol in Pediatric, Adolescent, and Young Adult Patients Who Have Undergone Allogeneic Bone Marrow Transplantation, Radiology, 226:399-404.
Runhua H., Goloubeva O., Neuberg D.S., Strominger J.L., and Wilson S.B. (2003), Interleukin-2 and Interleukin-12 promote iNK T cell proliferation, cytokine secretion and perforin expression independent of TCR activation, Immunology, 110: 30-37.
E. Paietta, O. Goloubeva, J. Bennett, R.Gallagher, J. Racevskis, P. Wiernik, M.Tallman., (2004), A surrogate marker profile for PML/RARa expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes, Cytometry B Clin Cytom, 59B: 1-9.
Wiernic PH, Paietta E, Makower D, Goloubeva OG., (2004), Phase II study of theophylline in chronic lymphocytic leukemia., Leukemia. Oct; 18 (10):1605-10.
Long BJ, Jelovac D, Handratta V, Thiatanawat A, MacPherson N, Ragas J, Goloubeva OG, Brodie AM., (2004), Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model, JNCI, 96:456-625.
Jelovac D, Macedo N., Handratta V,Long BJ, Goloubeva OG, Ingle JN, Brodie AM, (2004), Effects of exemestane and tamoxifen in a postmenopausal breast cancer model, Clinical Cancer Res 2004, Nov 1; 10(21): 7375-81.
Dutcher J., Gallagher R., Bennett J., Paietta E., Rowe J., Goloubeva O., Wiernik P. (2005) Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia. Leuk Lymphoma. Mar; 46(3): 377-85.
